Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
However, its also possible that your dose needs to be adjusted, or that you would benefit from some help in sticking with your medication plan
Early cardiovascular outcome trials of GLP-1RAs for diabetes included secondary kidney endpoints, typically defined by a 5-point composite renal outcome (CRO): increased urinary albumin-to-creatinine ratio, new-onset macroalbuminuria, sustained decline in estimated glomerular filtration rate (eGFR), initiation of chronic renal replacement therapy, and renal death.[15, 16] In patients with T2DM, GLP-1RAs significantly reduced CRO incidence, primarily driven by an 18% reduction in new-onset macroalbuminuria.[47] More recently, the FLOW trial, a dedicated kidney outcome trial in patients with T2DM and CKD, was terminated early due to overwhelming efficacy and mortality benefit.[24] FLOW revealed that semaglutide reduced the risk of a composite kidney outcome by 24% compared to placebo.[24] Emerging data suggest GLP-1RAs may also offer kidney benefits in populations without diabetes.[48] The SELECT trial demonstrated a reduced risk of persistent eGFR decline in patients with obesity and cardiovascular disease treated with semaglutide.[15] Additionally, a meta-analysis of placebo-controlled RCTs reported a slower decline in eGFR over one year in individuals with a baseline eGFR 3060 mL/min/1.73m 2 treated with GLP-1RAs regardless of diabetes status.[12] These findings support the potential utility of GLP-1RAs in CKD patients without diabetes, and additional dedicated trials are underway to validate these outcomes in populations without diabetes
2018 Apr;57(3):965-979
Cost and Insurance Coverage GLP-1 medications may be costly without insurance coverage
